BMY Financials Bristol Myers Squibb

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 45 d ago Overview →

Growth & profitability

Revenue has grown 2.5% per year over the past 5 years.
Free cash flow has declined 0.7% per year over the past 5 years.

Financial health

Total debt ($47.1B) exceeds cash ($10.2B); net debt is $36.9B.
Total debt has grown slower than revenue (-2.2% vs 2.5% per year).

Shareholder returns

Dividends have been paid for 15 consecutive years, consuming 71.5% of earnings and 39.3% of free cash flow.
The dividend has grown 4.4% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$48.2B	$7.1B	71.1%	0.0%	38.2%	7.8%	$12.8B	$47.1B	$10.2B
2024	$48.3B	-$8.9B	71.1%	0.0%	-54.8%	-9.7%	$13.9B	$51.5B	$10.3B
2023	$45.0B	$8.0B	76.2%	0.0%	27.3%	8.4%	$12.7B	$42.6B	$11.5B
2022	$46.2B	$6.3B	78.0%	0.0%	20.4%	6.5%	$11.9B	$43.2B	$9.1B
2021	$46.4B	$7.0B	78.6%	0.0%	19.5%	6.4%	$15.2B	$49.3B	$14.0B
2020	$42.5B	-$9.0B	72.3%	0.0%	-23.8%	-7.6%	$13.3B	$52.7B	$14.5B
2019	$26.1B	$3.4B	69.1%	0.0%	6.7%	2.6%	$7.4B	$49.5B	$12.3B
2018	$22.6B	$4.9B	71.3%	0.0%	35.1%	14.1%	$6.1B	$8.6B	$6.9B
2017	$20.8B	$1.0B	70.7%	0.0%	8.6%	3.0%	$4.2B	$8.0B	$5.4B
2016	$19.4B	$4.5B	74.5%	0.0%	27.6%	13.2%	$1.8B	$6.6B	$4.2B
2015	—	$1.6B	—	—	11.0%	4.9%	$1.3B	$6.7B	$2.4B
2014	—	$2.0B	—	—	13.5%	5.9%	$2.6B	$7.8B	$5.6B
2013	—	$2.6B	—	—	16.9%	6.6%	$3.0B	$8.3B	$3.6B
2012	—	$2.0B	—	—	14.4%	5.5%	$6.4B	$8.1B	$1.7B
2011	—	$3.7B	—	—	23.2%	11.2%	$4.5B	$5.5B	$5.8B

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$13.0B	$3.3B	71.3%	0.0%	14.9%	3.8%	$3.1B	$43.9B	$8.7B
Mar '26	$11.5B	$2.7B	70.2%	0.0%	13.3%	3.1%	$757M	$46.4B	$9.6B
Dec '25	$12.5B	$1.1B	67.2%	0.0%	5.9%	1.2%	$1.6B	$47.1B	$10.2B
Sep '25	$12.2B	$2.2B	71.9%	0.0%	11.9%	2.3%	$6.0B	$53.2B	$15.7B
Jun '25	$12.3B	$1.3B	72.5%	0.0%	7.5%	1.4%	$3.6B	$53.7B	$12.6B
Mar '25	$11.2B	$2.5B	72.9%	0.0%	14.1%	2.7%	$1.7B	$53.1B	$10.9B
Dec '24	$12.3B	$72M	61.0%	0.0%	0.4%	0.1%	$4.1B	$51.5B	$10.3B
Sep '24	$11.9B	$1.2B	75.1%	0.0%	7.1%	1.3%	$5.3B	$50.6B	$7.9B
Jun '24	$12.2B	$1.7B	73.2%	0.0%	9.9%	1.8%	$2.1B	$55.5B	$6.3B
Mar '24	$11.9B	-$11.9B	75.3%	0.0%	-72.2%	-12.0%	$2.5B	$58.5B	$9.3B
Dec '23	$11.5B	$1.8B	76.1%	0.0%	6.0%	1.9%	$3.9B	$42.6B	$11.5B
Sep '23	$11.0B	$1.9B	77.1%	0.0%	6.6%	2.1%	$4.4B	$42.5B	$7.5B
Jun '23	$11.2B	$2.1B	74.4%	0.0%	6.5%	2.2%	$1.6B	$40.1B	$8.4B
Mar '23	$11.3B	$2.3B	77.4%	0.0%	7.1%	2.4%	$2.7B	$40.1B	$9.0B
Dec '22	$11.4B	$2.0B	77.3%	0.0%	6.5%	2.1%	$3.0B	$43.2B	$9.1B
Sep '22	$11.2B	$1.6B	79.0%	0.0%	4.9%	1.6%	$3.4B	$41.0B	$7.7B
Jun '22	$11.9B	$1.4B	77.1%	0.0%	4.4%	1.4%	$2.0B	$46.7B	$10.8B
Mar '22	$11.6B	$1.3B	78.8%	0.0%	4.0%	1.2%	$3.6B	$52.3B	$12.4B
Dec '21	$12.0B	$2.4B	80.3%	0.0%	6.6%	2.2%	$3.7B	$49.3B	$14.0B
Sep '21	$11.6B	$1.5B	80.3%	0.0%	4.2%	1.4%	$5.0B	$49.5B	$13.5B

Valuation over time

How the market has priced BMY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 22.4× (Mar '23) to 19.7× (Sep '26).
The price-to-sales ratio has fallen from 3.1× (Mar '23) to 2.9× (Sep '26).
The dividend yield has risen from 3.3% (Mar '23) to 3.6% (Sep '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is BMY growing its revenue and profit?

Over the past 5 years, Bristol Myers Squibb's revenue has grown 2.5% per year. These are computed facts, not advice.

How much debt does BMY have?

As of FY2025, Bristol Myers Squibb reported $47.1B of total debt against $10.2B of cash.

What is BMY's profit margin?

In FY2025, gross margin was 71.1%, operating margin —, and net margin 14.6%.

What is BMY's P/E ratio?

As of Sep '26, Bristol Myers Squibb traded at a price-to-earnings ratio of about 19.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.